Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse eventsSeptember 20, 2017Immuno-oncologyImmunotherapyLung Cancer
Adding T-vec might help surmount PD-1 resistance in melanomaSeptember 14, 2017Immuno-oncologyMelanomaImmunotherapy
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanomaSeptember 11, 2017Immuno-oncologyMelanoma
Pembrolizumab, nivolumab linked to 3% rate of neurologic eventsSeptember 5, 2017Immuno-oncologyPatient & Survivor CareMelanomaLung CancerRenal Cell CarcinomaHead & Neck/Thyroid CancersNeuro-oncology
FDA approves first gene therapy – tisagenlecleucel for ALLAugust 30, 2017Leukemia, Myelodysplasia, TransplantationPediatricsImmuno-oncology
Adverse effects of PD-1/PD-L1 inhibitors varied by tumor type in systematic reviewAugust 28, 2017Immuno-oncologyImmunotherapyMelanomaRenal Cell CarcinomaLung Cancer
FDA approves nivolumab for metastatic CRCAugust 2, 2017GastroenterologyImmuno-oncologyImmunotherapyGastrointestinal Cancer
Enasidenib gets FDA approval for AML with IDH2 mutationsAugust 1, 2017Leukemia, Myelodysplasia, TransplantationImmuno-oncology
New SU2C translational team aims to apply CAR T-cell therapy to pancreatic cancerAugust 1, 2017Immuno-oncologyGastroenterologyImmunotherapyGastrointestinal Cancer
Avelumab induces response in Hodgkin lymphoma after failed allo-SCTJuly 20, 2017Lymphoma & Plasma Cell DisordersImmuno-oncology
IMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Lymphoma & Plasma Cell DisordersImmuno-oncologyFollicular Lymphoma
All FDA panel members go thumbs up for CTL019 in relapsed/refractory childhood ALLJuly 12, 2017Leukemia, Myelodysplasia, TransplantationImmuno-oncology
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastasesJune 12, 2017MelanomaImmuno-oncologyImmunotherapyCNS/Brain Cancer
